Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

New male birth control pill could work in minutes

NCT ID NCT07393334

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now This study
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This study tests a new non-hormonal male contraceptive called NLS-133, taken just before sex to reduce sperm count and semen volume. Ten healthy men will receive the drug, an active control, or a placebo in random order. The goal is to see if it safely and effectively lowers sperm count and motility.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
NLS-133 (combination of two FDA-approved drugs)
What this could lead to
If it works, this could lead to a new non-hormonal, on-demand male contraceptive pill.
What could go wrong
This is a very small early-phase trial with only 10 men, so results may not apply widely. The drug is taken just before sex, so effectiveness and safety are still uncertain.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Phase 2

Tests whether the treatment actually works, and watches for side effects, in a larger group.

Participants

About 10 people

The number the study aims to enrol. It can still change while the study runs.

Started

Dec 2025

Expected to finish

May 2026

An estimate. End dates often move.

Lead sponsor

A company

The lead sponsor is a pharmaceutical, biotech, or medical-device company.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

18 to 55 years

Sex

Male participants only

Healthy volunteers

Accepted

You do not need to have the condition being studied to take part.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: 1. Male, age 18-55. 2. Normal physical examination and testicular volume \>15 cc 3. No significant medical history that would impact the safety of the study. 4. No current use of drugs that comprise NLS-133 5. Normal values on baseline hematology, blood chemistry and liver function tests and serum testosterone. 6. Normal baseline sperm parameters (semen volume \>1.4 cc, sperm concentration \>15 million/ml, motility \>40% and morphology \>4%). 7. Willing and able to comply with all study requirements and procedures. Exclusion Criteria: 1. History or evidence of erectile dysfunction. 2. Inability to produce semen samples in clinic setting. 3. Significant chronic or acute medical illness. 4. Previous or current ethanol or illicit drug abuse. 5. Evidence of significant underlying disease (based on results of the physical exam and the routine labs). 6. Known infertility or hypogonadism. 7. Planned or anticipated use of any prohibited medications during participation in the study. These include use of sex hormones for treatment, testosterone, anabolic steroids, retinoic acid (e.g., Accutane®), vitamin A, other drugs known to inhibit spermatogenesis, opioids, cocaine, methamphetamine, and/or the consumption of \>4 alcoholic beverages daily. 8. Presence of moderate-to-severe pulmonary or cardiovascular disease 9. Known active hepatitis B, hepatitis C, human immunodeficiency virus (HIV), or COVID-19 infection. 10. History of malignancy within 5 years before the Screening Visit, except fully treated and resolved non-metastatic squamous or basal cell carcinoma of the skin. 11. Known active chronic or acute infection requiring treatment with systemic antibiotics, antivirals, antifungals, antiparasitics or antiprotozoals during the Screening period. 12. Any other acute or chronic medical or psychiatric condition or laboratory abnormality that could increase the risk associated with study participation in the judgment of the investigator would make the participant inappropriate for entry into the study. 13. Participation in another investigational clinical trial within the last 30 days. 14. Participants who live in detention on court order or on regulatory action. 15. Related to sponsor or staff involved in the conduct of the study.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Male contraception are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

How to take part

Only the study team decides who joins. These are the ways to reach them.

  1. The places running it

    1 site. The list below names each one and where it is.

  2. The official record

    ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.

    Open the record ↗

  3. A doctor treating you

    A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.

Contacts and locations

Locations

  • Population Center for Research in Human Reproduction and Departments of Medicine, University of Washington

    RECRUITING

    Seattle, Washington, 98195, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.